Notes
The study was supported by an unrestricted research grant from Almirall S.p.A.
Reference
Mantovani LG, et al. Cost-Effectiveness Analysis of Cannabinoid Oromucosal Spray Use for the Management of Spasticity in Subjects with Multiple Sclerosis. Clinical Drug Investigation : 4 Mar 2020. Available from: URL: https://doi.org/10.1007/s40261-020-00895-6
Rights and permissions
About this article
Cite this article
Oromucosal cannabinoid for MS spasticity: benefits at acceptable cost. PharmacoEcon Outcomes News 849, 21 (2020). https://doi.org/10.1007/s40274-020-6672-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-020-6672-1